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Abstract: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and
is a leading cause of mortality worldwide. While there are many risk factors for HCC including
alcohol, obesity, and diabetes, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection still
account for the majority of HCC worldwide. Globally, HBV is the leading risk factor for HCC. Patients
with chronic hepatitis B (CHB) and advanced liver disease are at high risk for HCC. Screening for HCC
is done routinely with ultrasound with or without alpha-fetoprotein (AFP) at six-month intervals.
The combination of ultrasound and AFP has been shown to provide some additional detection
of 6–8% of cases compared to ultrasound alone; however, this also increases false-positive results.
This is because AFP can be elevated not only in the setting of HCC, but also in chronic hepatitis,
liver cirrhosis, or ALT flare in CHB, which limits the specificity of AFP. AFP-L3 is a subfraction of
AFP that is produced by malignant hepatocytes. The ratio of AFP-L3 to total AFP is reported as a
percentage, and over 10% AFP-L3 is consistent with a diagnosis of HCC. Here, we review five cases of
patients with CHB, cirrhosis, and HCC, and their levels of AFP and the AFP-L3% at various stages of
disease including ALT flare, cirrhosis, initial diagnosis of HCC, and recurrence of HCC. These cases
emphasize the utility of AFP-L3% in identifying early, new or recurrent HCC prior to the presence of
imaging findings.
Keywords: AFP; AFP-L3; hepatocellular carcinoma (HCC); hepatitis B virus (HBV); chronic hepatitis
B (CHB)
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1. Introduction

iations.

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the
liver and a leading cause of mortality worldwide [1]. HCC accounts for 600,000 deaths
worldwide (50% in China) and 10,000 deaths in the US annually. Globally, 53% of HCC is
attributed to hepatitis B virus (HBV) and 25% to hepatitis C virus (HCV) [1–3]. The disease
burden is highest in endemic regions of HBV infection [1].
There are many risk factors for HCC including alcohol, obesity, and diabetes, but HBV
and HCV infections account for the majority of HCC worldwide. Globally, HBV is the
leading risk factor for HCC [1].
For patients at high risk for HCC, surveillance by abdominal ultrasound (US) is used
as the first line modality, followed by dynamic computed tomography (CT) or magnetic resonance imaging (MRI). Imaging studies should be performed every 6 months (or 3 months
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if indicated) for detection of HCC. Most guidelines recommend imaging with concomitant
alpha-fetoprotein (AFP) level for HCC surveillance. However, AFP can be elevated not
only in HCC, but also other conditions such as pregnancy, chronic liver inflammation, and
during ALT flare. Therefore, AFP-L3 has been used as the specific tumor marker for HCC
during the recent years but not as routinely as AFP alone [4].
2. History of AFP
AFP is an alpha1 globulin containing glycoprotein and its level is increased during
pregnancy due to the production by the fetal liver. Elevated AFP level disappears from
serum within 3 weeks after childbirth [5].
Furthermore, elevated AFP during acute liver injury indicates active regeneration of
liver cells. Serum studies made before and after partial hepatectomy experiments in animals
have indicated that hepatocyte proliferation is related to alpha-fetoprotein production [6].
In acute liver failure due to acetaminophen liver injury, an increase in AFP was strongly
associated with a favorable outcome [7].
AFP as a marker for liver tumor was first demonstrated in mice by Abelev et al. in
1963 and in patients with liver cancer by Tatarinov in 1963 and 1964 [8–10]. Increased AFP
was also found in yolk sac tumors as described by Abelev et al. and Masopust et al. [8–11].
3. AFP L1, L2, and L3
AFP is a glycosylated protein and based on its binding capability to lectin Lens
Culinaris Agglutinin (LCA), and total AFP can be separated into three different glycoforms,
AFP-L1, AFP-L2, and AFP-L3. AFP-L1 does not bind LCA, and it is the major glycoform
produced by nonmalignant hepatocytes in patients with chronic hepatitis B (CHB) infection
or cirrhosis [4–6]. AFP-L2 has intermediate binding affinity to LCA and is produced by
yolk sac tumors and can be detected in the maternal serum during normal pregnancy [12].
AFP-L3 does bind LCA and is produced by malignant hepatocytes [4]. The current cut-off
value for L3% is 10%. Patients with AFP-L3 > 10% are consistent with HCC and could be
defined as more aggressive cancers, as HCC cells producing more AFP-L3 have been found
to have a tendency for early vascular invasion and intra-hepatic metastasis [4].
Ultrasound has a sensitivity of 78% for detecting HCC at any stage and 45% for
detecting early-stage HCC [13,14]. MRI and dynamic contrast-enhanced CT are both more
sensitive for detecting HCC but are not recommended as the primary imaging modality for
screening [15]. An alternative screening method to ultrasound alone is to include AFP at
6-month intervals with ultrasound. The sensitivity of ultrasound plus AFP for detecting
HCC at any stage is 97% and 63% for detecting early-stage HCC [13,14].
The AFP-L3 can be detected in the serum of approximately 35% of the patients with
small HCC (<2 cm). The AFP-L3-positive HCC has potential for rapid growth and early
metastasis. Compared to imaging techniques, it has been shown to have 9–12 months of
lead-time in early HCC recognition. Combined sensitivity of AFP-L3 for HCC is 56%, with
a specificity of >95 [13,14].
4. Methods
In this study we included patients with CHB who were followed by a hepatologist
and getting screened regularly for HCC between the years of 2008 and 2011. Selection of
patients was based on the presence of laboratory data, corresponding stored serum samples,
and imaging results. This case series study protocol was approved by the Institutional
Review Board at Thomas Jefferson University Hospital.
AFP and AFP-L3% were measured in serum samples of patients collected at various
times throughout their illness course. AFP, AFP-L3, and DCP were measured using a
microchip capillary electrophoresis and liquid-phase binding assay on a µTASWako i30
auto analyzer (Wako Diagnostics, Wako Life Sciences, Inc., Mountain View, CA, USA) [16].
The measurement range for AFP was between 0.3 and 1000 ng/mL. Previously, AFP-L3%
was only able to be calculated for AFP levels > 10 ng/mL. However, the auto analyzer used
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has high sensitivity for AFP-L3% at low AFP concentrations. AFP-L3% can be as long as
the AFP is over 0.6 ng/mL [16].
Imaging studies including CT scans and MRIs were retrospectively reviewed after
each of the patients were selected and select representative images were chosen by Dr.
Christopher Roth to be included in the figures.
5. Case Series of Patients with Chronic HBV Infection and Retrospective Review of
AFP-L3% throughout Disease Course
At our institution, AFP has been used routinely to screen for HCC in patients who
are at risk for development of HCC. AFP with AFP-L3 is measured when there is a strong
suspicion of HCC recurrence after tumor ablation, and in particular when a high level of
AFP was noted in patients without risk for HCC. We measured total AFP and %L3 in the
serial serum specimens collected over time, in patients with ALT flare, liver cirrhosis, HCC,
and recurrent HCC and along with radiological examination. The patients presented here
have been followed in our Liver Disease Prevention Center due to their diagnosis of HCC
and CHB.
6. ALT Flare/Cirrhosis
6.1. Case 1: A 59-Year-Old Male during ALT Flare
Case 1 studies a 59-year-old male who was diagnosed with HBV infection during
blood donation at age 20. At age 49, he presented with fatigue, ALT 625 U/L, HBeAg
positive, HBV DNA 4.2 × 109 copies/mL, and AFP 2148 ng/mL. Abdominal ultrasound
showed a coarse liver echogenicity without tumor. He was started on entecavir, and
6 months later ALT was down to 149 IU/L and HBV DNA became undetectable. At this
time his AFP was 1896 ng/mL.
As shown in Table 1, the patient’s serum specimen that showed AFP 1896 ng/mL was
retrospectively tested for % of L3, which was 4.4%. This low value of AFP-L3% suggested
that his elevated AFP was from regenerating liver cells during the ALT flare. One year
and two years later his AFP levels were 3 ng/mL with % L3 AFP of 0.5 with normal ALT,
suggesting resolution of the flare.
Table 1. Case 1. AFP, %L3, and ALT during each following year after initial elevation in AFP.
Date

AFP (ng/mL)

AFP-L3 (%)

ALT (IU/L)

Status

July 2008

1896

4.4

149

ALT flare, no HCC

June 2009

3

0.5

WNL

No ALT flare, no HCC

September 2010

3

0.5

WNL

No ALT flare, no HCC

6.2. Case 2: A 57-Year-Old Male with Liver Cirrhosis
A 57-year-old male was infected with HBV perinatally. He presented with fatigue,
abdominal distension, and lower extremity swelling, and an MRI done at that time showed
cirrhosis and signs of portal hypertension but no liver masses. Labs demonstrated an ALT
331 IU/L, AST 578 IU/L, HBV DNA 7.47 × 108 copies/mL, and AFP 558 ng/mL. He was
started on tenofovir 300 mg daily. Three months after the initiation of treatment the ALT
normalized, and 3 months later the HBV DNA became undetectable. Both ALT and AFP
were elevated initially and decreased one year after the antiviral treatment with complete
resolution of AFP to 6.5 ng/mL. Retrospective measurement of the serum samples for
AFP and %AFP-L3 during the antiviral treatment showed nearly all below 10%, which is
consistent with AFP elevation due to cirrhosis/ALT flare rather than HCC as shown in
Table 2.
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Table 2. Case 2. AFP, L3%, and ALT at the time of cirrhosis diagnosis and after initiation of treatment.
Date

AFP (ng/mL)

AFP-L3 (%)

ALT (IU/L)

Status

June 2011

195.6

6.9

331

Cirrhosis

June 2011

315.7

8.9

336

Cirrhosis

June 2011

360.9

10.4

250

Cirrhosis

July 2011

332.8

11.5

150

Cirrhosis

September 2012

85.7

8.7

32

Cirrhosis

6.3. Case 3: A 59-Year-Old Male with HCC
A 59-year-old male with CHB was started on lamivudine 150 mg daily that resulted in
a negative HBV DNA and HBeAg seroconversion in 5 months of therapy. Three months
later, AFP was 544.5 ng/mL, and abdominal MRI showed a 3.3 × 2.4 cm enhancing mass
compatible with HCC. He underwent laparoscopic radiofrequency tumor ablation with
success. Four months later, the AFP was 2.2 ng/mL, and the MRI showed no recurrence
or new lesions of HCC. Four months later, the AFP was 8.4 ng/mL, and the abdominal
MRI showed two new small lesions, concerning for the recurrence of HCC. Retrospective
evaluation of %L3 of this AFP sample showed 74.2% consistent with HCC (Table 3 below).
Table 3. Case 3. AFP, L3%, and ALT at time of HCC recurrence.
Date

AFP (ng/mL)

AFP-L3 (%)

ALT (IU/L)

Status

July 2004

8.4

74.2

49

HCC recurrence

6.4. Case 4: A 50-Year-Old Male
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A 50-year-old male was diagnosed with CHB at age 40. With lamivudine treatment for
3 years, he achieved HbsAg seroconversion to anti-HBs and lamivudine was discontinued.
Table 4 outlines his course. Five years later, on a follow up examination he was found to
have HBV DNA 847 copies/mL, ALT 33 IU/L, and AFP 20.5 ng/mL. An MRI (December
2009) showed a 5 cm lesion consistent with HCC (Figure 1A,B). Repeat AFP was 17.8 ng/mL
at time of HCC diagnosis, and AFP-L3% was 75.6. He underwent transarterial chemoembolization (TACE) with successful resolution (Figure 2A,B) and restarted lamivudine. The
AFP remained at 3.0 ng/mL, and the MRI showed no evidence of HCC the following year.
Two years after initial treatment, the AFP increased to 5.9 ng/mL with 57.5% L3. The MRI
5 of 10
next month showed recurrent HCC at the treated site (Figure 3). The patient underwent
laparoscopic radiofrequency ablation and therasphere treatment.
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Table 4. Case 4. AFP, L3%, ALT, and MRI findings at various times throughout treatment course.
Date

AFP (ng/mL)

AFP-L3 (%)

ALT (IU/L)

MRI

HCC Treatment

December 2009

17.8

75.6

33

5 cm HCC (Figure 1A,B)

TACE (Figure 2A,B)

March 2010

3.0

0.5

29

No evidence of HCC

August 2010

2.5

0.5

25

No evidence of HCC

March 2011

5.9

57.5

48

April 2011
May 2011
June 2011
July 2011

Recurrent HCC
(Figure 3A–C)
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Subsequent %L3 AFPs remained persistently high with minimally elevated total AFP
levels, which indicated recurrent/progressive HCC.
6.5. Case 5: A 58-Year-Old Male
A 58-year-old male was found to have CHB on a routine examination in May 2007.
HBV DNA was 4.6 × 105 copies/mL. He was started on telbivudine. The AFP was
3.2 ng/mL in May 2008 with AFP-L3% of 13.8. The MRI in July 2008 showed cirrhosis and
no tumor. In August 2008, the AFP remained low at 3.2 ng/mL, but there was a rise in
the AFP-L3% to 33.6. The AFP-L3% continued to rise to 69.7 by November 2008, while the
absolute AFP value remained at 7.9 ng/mL. In March 2009, the AFP rose to 24.1 ng/mL,
and the AFP-L3% at this time was continuing to rise to 87.7. At this time, the abdominal
MRI showed a 2.4 × 2.0 cm HCC. He underwent cryoablation followed by radiofrequency
tumor ablation and TACE (March and August 2009). These values are outlined in Table 5.
Table 5. Case 5. AFP, L3%, ALT, and imaging findings at time of HCC screening, diagnosis, and at
various treatment points.
Date

AFP (ng/mL)

AFP-L3 (%)

ALT (IU/mL)

MRI

May 2008

3.2

13.8

32

No tumor

August 2008

3.2

33.6

20

July 2008
(Figure 4A,B)
Indeterminate

November 2008

7.9

69.7

30

No tumor
visualized

March 2009

24.1

87.7

17

2.4 × 2.0 HCC
(Figure 5A–C)

March 2009

16.6

88.8

23

HCC

April 2009
May 2009
August
2009
Viruses
2022, 14,
x
July 2010

HCC Treatment

Cryoablation
(Figure 6A,B)
6.7

74.7

20 (8/17/09)

new HCC
(Figure 7A–D)
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Figure 4. Initial MRI with normal AFP and elevated %L3 (July 2008). (A) The axial T2-weighted
gradient echo image shows a small hyperintense lesion (arrow) in segment 4A. A second
hyperintensity (dashed arrow) corresponds to a hemangioma. (B) The corresponding axial T1Figure 4. Initial MRI with normal AFP and elevated %L3 (July 2008). (A) The axial T2-weighted
weighted fat-suppressed arterial-phase postcontrast image shows hyperenhancement (arrow) in the
gradient echo image shows a small hyperintense lesion (arrow) in segment 4A. A second
lesion subsequently found to be a small HCC, although currently without associated features 7toof 10
hyperintensity (dashed arrow) corresponds to a hemangioma. (B) The corresponding axial T1clinch the
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the
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lesion subsequently found to be a small HCC, although currently without associated features to
clinch the diagnosis. Without washout, capsule appearance, or other typical HCC findings, the
lesion is indeterminate.
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Figure 6. Cryoablation of the segment 4A HCC (April and May 2009). (A) The CT image through
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MRI showedimage
threshold
growth of
the hyperenhancing
(arrows).(C)
(D)Months
The corresponding
diffusion-weighted
growth
of the hyperenhancing
lesion
(arrows).
The corresponding
image
shows diffusion
restriction (arrows)
and
helps to (D)
confirm
the diagnosis ofdiffusion-weighted
HCC (as an ancillary
feature);
washoutrestriction
was also evident
(notand
shown),
confirming
thethe
diagnosis
of HCC.
shows
diffusion
(arrows)
helps
to confirm
diagnosis
of HCC (as an ancillary
feature); washout was also evident (not shown), confirming the diagnosis of HCC.

7. Discussion and Conclusions
We present this case series of five patients with HBV infection who have elevations
in AFP at various points in their disease course. We retrospectively analyzed the %L3 of
AFP in these samples to evaluate for the possibility of usefulness of routine L3%
evaluation along with AFP screening in patients with CHB at risk for HCC.
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7. Discussion and Conclusions
We present this case series of five patients with HBV infection who have elevations
in AFP at various points in their disease course. We retrospectively analyzed the %L3 of
AFP in these samples to evaluate for the possibility of usefulness of routine L3% evaluation
along with AFP screening in patients with CHB at risk for HCC.
Of the five patients, Case 1 had CHB with ALT flare and Case 2 had liver cirrhosis.
Both had elevated AFP levels with a relatively low percentage of AFP-L3 (usually below
10%) in the setting of nonmalignant hepatocellular damage and concomitant liver cell
regeneration. No signs of tumor recurrence were noted in these patients.
Cases 3, 4, and 5 demonstrate patients with levels of AFP and L3% varying at different
points in their disease course including time of HCC diagnosis, resolution of HCC, and
recurrence of HCC. They demonstrate high AFP with elevated L3% correlating with active
HCC disease. Specifically for Case 5, we can see rising AFP-L3% (>10%) prior to a significant
absolute increase in the value of AFP and prior to HCC being identified on imaging. This
suggests the use of AFP-L3% being used as an early screening marker to detect small HCCs
that are not yet detectable by AFP values alone or on imaging. We see in each of these cases,
when HCC is present, regardless of the level of AFP alone, the L3% is greater than 10%,
which demonstrates that L3% specifically may be highly sensitive for detection of initial
disease as well as recurrence.
These cases also demonstrate the utility of AFP-L3% for monitoring for recurrence
in patients who have had HCC treated. This is demonstrated nicely in Case 4, as the AFP
value and AFP-L3% came down significantly after TACE treatment in concordance with
imaging findings indicating resolution of HCC. This resolution was followed by an abrupt
and significant rise in AFP-L3% (57.5% from 0.5%), which was associated with a relatively
smaller and nonspecific rise in the absolute value of AFP (5.9 ng/mL from 2.5 ng/mL) with
subsequent imaging findings consistent with recurrent HCC.
Overall, these cases demonstrate the utility of AFP-L3% in differentiating between
various causes of AFP elevation including ALT flare, cirrhosis, and HCC, and the utility for
early detection of HCC and recurrence after treatment. The usefulness of the combination of
AFP, AFP-L3, and DCP for early detection of HCC is evident, and notably the GALAD scoring algorithm, which has been reported in the past [16–20]. In our similar study, we further
noted that AFP-L3 is particularly useful in predicting the recurrence of HCC after tumor
ablation [16]. Our current study re-confirmed the significance of AFP-L3 for early detection
of recurrence in the presence of low AFP and long before the radiological confirmation.
This use of AFP-L3% in conjunction with standard imaging +/− AFP screening
warrants further studies to demonstrate the utility in routine HCC screening. In a study
done by Hann et al. in 2014, they noted that AFP-L3% was useful in patients with low
levels of AFP (<20 ng/mL), and they saw that a significant AFP-L3% elevation could be
detected over one year before the diagnosis of HCC as well as predicting recurrence of
HCC [16]. These cases demonstrate the need for more studies to further support the use of
AFP-L3% in early detection of HCC before a small lesion is able to be detected on imaging
and before a significant rise in absolute AFP value is detected.
The use of AFP for routine HCC screening is controversial and is often regarded as a
better tool for monitoring treatment response and recurrence rather than a tool for initial
diagnosis. This is likely because AFP can be elevated for a number of non-malignant
reasons, which may lead to unnecessary additional imaging. It is therefore possible that,
by measuring the %L3 in addition to AFP, it can increase the diagnostic power of AFP by
helping to distinguish an AFP elevation due to nonmalignant hepatic inflammation from
HCC development and recurrence.
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